A Track Record of Success
Ten to fifteen years is too long for a person with a life-threatening illness to wait for a new treatment or cure, yet that is the average timeframe for potential new drugs to make it to the marketplace. Identifying the underlying cause of a disease is the first step in the drug discovery process.
In the past decade alone, Institute faculty have:
- Made revolutionary discoveries, based on the convergence of chemistry, physics, engineering and life sciences, for detection and treatment of cancer, infertility, common and rare neurodegenerative diseases, and imaging and manipulation of cell behavior
- Advanced 75 new drug candidates, medical devices, and diagnostics, collectively, toward clinical trials, including a new class of drugs to treat epilepsy, new compounds for psychiatric treatment, therapeutics for Wilson’s disease, and improved treatment for macular degeneration
- Spun out 27 new companies have spun out of the Institute and received external investments exceeding $1.5 billion
And the Institute has:
- Acquired more than 50 new instruments and created new services to accelerate transdisciplinary research
- Developed new 21st century curricula and activities to support development of next gen scientists working across disciplinary boundaries to address the big questions in biomedical research
- Raised more than $50 million in new external funding to support these efforts
Attracting Early Stage Investment
Chemistry of Life Processes Institute partners with investment firms to introduce the translational research of some our most innovative faculty members to early stage biotech/pharma investors and industry leaders. These programs ensure continued financial support from the investment community that in turn drives future scientific exploration and innovation.
In March 2019, CLP and Oppenheimer & Co. co-hosted ‘Biotech Summit by the Lake,’ and all-day investor conference that drew approximately 100 investors, venture firms and biotech and pharmaceutical industry members from across the US for a full day of presentations, a lunchtime panel discussion and networking opportunities. Following the conference, Oppenheimer’s biotech research analysts published an industry report highlighting CLP’s growing reputation as a biotech incubator and major hub for drug discovery and development in the Chicago-region.
CLP Institute’s Entrepreneur-in-Residence program, one of the first academic programs of its kind in the nation, helps move discoveries out of the lab and into clinics.
William Sargent, PhD, provides mentoring in the drug development process, from initiation to FDA marketing approval, to interested researchers across campus looking to explore commercialization. Bill has over 30 years in the pharmaceutical industry, preceded by 10 years as an independent researcher in academia. He is available on both the Chicago and Evanston campuses to consult with faculty, students and staff interested in developing potential therapies emerging from their translational research.
Companies Founded by CLP Faculty
Founders: Cheng Sun, Hao Zheng
Founder: Olga Volpert
Co-Founder: Jack Henkin
Founder: Thomas Meade
Founder: Thomas O’Halloran
Co-Founder: Chandler Robinson
Founder: Richard Silverman
Co-Founders: Dmitri Krainc
Founder: Jack Henkin
Co-Founders: Andrew Mazar, Olga Volpert
Northwestern Partners in Entrepreneurship
INVO catalyzes the translation of Northwestern innovations to benefit the public and promote economic growth. In order to maximize that outcome, Northwestern follows important principles when licensing university technology.
NewCures is a Northwestern initiative that focuses on accelerating biomedical research from early discovery stages to more advanced clinical stages for the benefit of the patients. The NewCures Fund aligns with existing resources to propel promising therapies towards commercialization.
Entrepreneurs-in-Residence (EIR) advise and assist faculty and students who are launching startups and commercializing IP. They are a resource for developing business concepts, making contacts with the market, connecting to investors, and forming organizational frameworks.
The CBC stimulates collaboration among researchers at Northwestern University, The University of Chicago, the University of Illinois at Chicago, and others to accelerate discovery that transforms biomedical research and improves the health of humankind.
Northwestern University researchers have, for the first time, determined the 3D atomic structure of a key complex in paramyxoviruses, a family of viruses that includes mumps, human parainfluenza and respiratory syncytial virus (RSV). This information could help others...
Veteran entrepreneurs and cofounders of Actuate Therapeutics, Inc., Daniel Schmitt and Andrew Mazar, PhD, are taking no chances with their lead clinical candidate 9-ING-41, a promising new treatment for advanced and drug-resistant cancers and select inflammatory...
Treating severe brain injury often requires immediate surgery, including implantation of an electronic sensor that monitors tissues and fluids and digitally provides real-time information about intracranial pressure, temperature and wound healing. These devices,...
The deaths were palpable. Just six years after the start of a medical career he envisioned would be filled with helping patients heal, Richard D’Aquila, instead, found himself at the forefront of the AIDS epidemic. What he did next continues to alter the lives of...